Clinical Trials
101 trialsA Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Thomas Jefferson University
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia
Masonic Cancer Center, University of Minnesota
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
Stanford University
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
University of Pittsburgh
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
City of Hope Medical Center
FluBuBe
St. Petersburg State Pavlov Medical University
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
City of Hope Medical Center
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
M.D. Anderson Cancer Center
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
University of Nebraska
FluBuATG
Dartmouth-Hitchcock Medical Center
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
M.D. Anderson Cancer Center
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
M.D. Anderson Cancer Center
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
HaploOnly
University of Rochester
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
H. Lee Moffitt Cancer Center and Research Institute
GITMO-MF2010
Gruppo Italiano Trapianto di Midollo Osseo
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Roswell Park Cancer Institute
AML/MDS/JMML
Columbia University
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation
National Institutes of Health Clinical Center (CC)
Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
Combined Haploidentical-Cord Blood Transplantation for Adults and Children
University of Chicago
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
M.D. Anderson Cancer Center
IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Bone Marrow Transplant in Treating Patients With Hematologic Cancers
H. Lee Moffitt Cancer Center and Research Institute
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
M.D. Anderson Cancer Center
Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)
medac GmbH
Cord Blood Expansion on Mesenchymal Stem Cells
M.D. Anderson Cancer Center
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
Roswell Park Cancer Institute
ALBUM
University of Arizona
Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
University of Illinois at Chicago
Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
New York Medical College
Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine
Memorial Sloan Kettering Cancer Center
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
St. Petersburg State Pavlov Medical University
Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers
University of California, Davis
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
University of California, San Francisco
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
University of California, San Francisco
Bu Flu TBI
OHSU Knight Cancer Institute
LCCC0510
UNC Lineberger Comprehensive Cancer Center
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation
Massachusetts General Hospital
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute